Close
Achema

Naprod Life Sciences successfully renews EU-GMP Certification for its Palghar facility

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

The Realities of the Nursing Shortage in Rural America

Along with multiple public health crises, the United States...

Green List by FDA to Cut Illegal GLP-1 Active Ingredients

The U.S. Food and Drug Administration has gone on...

Naprod Life Sciences (Naprod) announced today the successful renewal of its European Union Goods Manufacturing Practices (EU-GMP) certification for its manufacturing facility in Palghar. The approval marks a significant milestone for Naprod in its journey of global leadership. The audit was conducted in December 2023 by The National Institute of Pharmacy and Nutrition (OGYÉI), Hungary.

Speaking on the development, Mr. Mohan Jain, Managing Director at Naprod Life Sciences said, “The EU GMP certification for our facility in Palghar is a testament to our consistent efforts to comply with the highest quality standards. We are committed to being compliant and supplying quality products to our customers and patients across the globe.”

The EU-GMP certification highlights the Palghar facility’s capabilities to ensure consistent and controlled production in accordance with the EU’s quality standards. The facility produces a wide range of formulations, liquid and lyophilised injectable products, with a special focus on oncology, anaesthetics and other therapy segments.

Latest stories

Related stories

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

The Realities of the Nursing Shortage in Rural America

Along with multiple public health crises, the United States...

Green List by FDA to Cut Illegal GLP-1 Active Ingredients

The U.S. Food and Drug Administration has gone on...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back